OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Neurology is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
Lymphatic propagation of α-synuclein	456
Microglia, spreaders of Aβ seeds	403
Transmembrane protein interacts with α-synuclein to confer risk of PD	342
Promising results for antisense RNA therapy in mouse models of diffuse midline glioma	271
Ventricular enlargement caused by aducanumab	270
Getting specific: targeting Fc receptors in myasthenia gravis	244
Brain stimulation aids walking after spinal injury	241
Epstein–Barr virus as a leading cause of multiple sclerosis: mechanisms and implications	226
Neural cell state shifts and fate loss in ageing and age-related diseases	223
Deciphering nociplastic pain: clinical features, risk factors and potential mechanisms	208
Diagnosis and management of migraine in ten steps	192
Refining oxytocin therapy for autism: context is key	186
Global synergistic actions to improve brain health for human development	186
NODDI reveals brain microstructural changes in multiple sclerosis	185
Disease-specific modifications of tau protein	179
Continuous levodopa production by an artificial enzyme	174
CD11c+ macrophages mediate brain-to-gut α-synuclein trafficking	173
The impact of rare genetic variants on Alzheimer disease	172
Spinal muscular atrophy treatment in utero	159
Nir Giladi (1955–2024)	157
Mitochondrial DNA instability in Huntington disease	155
Study reveals new ALS risk genes	134
Microglia subset associated with high-grade glioma	131
Rapidly progressive dementias — leukodystrophies as a potentially treatable cause	129
Is post-stroke cognitive impairment all about real estate?	128

TREM2 mediates phagocytosis in glioblastoma	126
Imperatives and co-benefits of research into climate change and neurological disease	119
SEQUINS — a new initiative to address disparities in neurology	118
The Digitized Memory Clinic	114
Amyloid-β: a potential link between epilepsy and cognitive decline	113
Maternal immune activation and neuroinflammation in human neurodevelopmental disorders	110
The role of the gut microbiota in multiple sclerosis	108
Ultrasound lets gene therapy into the brain	102
Brain volume is associated with cognition in MS	101
Role for endogenous retrovirus in FTD	99
Menopause influences tau pathology	98
Amyloid plaques: hotspots for microglial turnover	97
Neurological care for LGBT+ people	96
Psychosis-causing lesions mapped to a hippocampal circuit	91
The challenges of anti-tau therapeutics in Alzheimer disease	90
Neuroinflammation predicts cognitive decline in FTD	88
Implications of AD plasma and PET biomarker discordance	87
Gene therapy effective in model of infantile parkinsonism	86
Diversity, equity and inclusion in neurology	84
MRI-based deep learning for TLE diagnosis	84
APOE ε4 influences Parkinson disease progression	81
Brain imaging illuminates cognitive impairment in multiple sclerosis	81
Author Correction: Viral pathogens increase risk of neurodegenerative disease	75
First trials test targeting of α-synuclein for Parkinson disease	74
Gene therapy for seizures in focal cortical dysplasia	74
Parkinson disease pathology can originate in the kidney	73
The noradrenergic subtype of Parkinson disease: from animal models to clinical practice	68
Management of freezing of gait — mechanism-based practical recommendations	68
Precision neuroimmunology in multiple sclerosis — the horizon is near	68
Blood GFAP as an emerging biomarker in brain and spinal cord disorders	67
α-Synuclein pathology as a target in neurodegenerative diseases	66
Evidence for altered astrocyte function in Duchenne muscular dystrophy	66
New IDEAS about amyloid, race and dementia disparities	65
Author Correction: Why won’t it stop? The dynamics of benzodiazepine resistance in status epilepticus	64
Food is brain medicine — relevance and translation to neurology	63
Neurosteroids alleviate seizures in rats	62
Glymphatic dysfunction in PD clinical progression	61
A new biological classification for Parkinson disease	60
Thalamic inflammation — a therapeutic target for brain injury?	60
Exosomal microRNA is promising biomarker in PD	58
Addressing disparities in neurology by building the workforce in LMICs	57
Ultrasound ablation treatment for PD	55
Spinal cord stimulation for the treatment of chronic pain	55
Coeliac disease as a model for understanding multiple sclerosis	54
The global and regional burden of diabetic peripheral neuropathy	52
Knowing the enemy: strategic targeting of complement to treat Alzheimer disease	51
Post-COVID dysautonomias: what we know and (mainly) what we don’t know	51
Apparent changes in the epidemiology and severity of multiple sclerosis	51
The role of glial cells in multiple sclerosis disease progression	50
From the prodromal stage of multiple sclerosis to disease prevention	49

Why won’t it stop? The dynamics of benzodiazepine resistance in status epilepticus	49
Synaptic degeneration in Alzheimer disease	48
Is Alzheimer disease a disease?	48
Hypothalamus loses control in migraine	46
Oligomeric tau could spread through synapses in AD	42
Hypothyroidism is associated with dementia risk	42
X-chromosome variants and PD in Latin America	42
Continuing evolution of migraine-specific therapies — targeting migraine with precision and persistence	41
Genetic susceptibility determines Epstein–Barr-virus-associated risk of multiple sclerosis	41
Peripheral nervous system immune-related adverse events due to checkpoint inhibition	41
Neurofilament light chain induces neuroinflammation	40
Limbic-predominant age-related TDP43 encephalopathy (LATE) neuropathological change in neurodegenerative diseases	40
Cognitive impairment and World Trade Centre-related exposures	38
The inter-relationship between delirium and dementia: the importance of delirium prevention	38
Global epidemiology of migraine and its implications for public health and health policy	38
Safety and efficacy of COVID-19 vaccines in people with neurological disorders	37
CAR T cells offer hope in glioblastoma	37
T cells implicate Epstein–Barr virus in multiple sclerosis pathogenesis	36
Insights from 25 years of onabotulinumtoxinA in migraine — mechanisms and management	36
Dual function of biomolecular condensates	35
α-Synuclein seeds in amyotrophic lateral sclerosis	35
Moving towards meaningful patient and public engagement	35
Risk locus for paediatric astrocytoma identified	35
Impaired glymphatic drainage links amyloid and tau to cognitive dysfunction	35
Multi-ancestry GWAS identifies 16 novel Alzheimer disease risk loci	33
Change in stroke outcomes over 20 years	33
New developments in guidelines for brain death/death by neurological criteria	32
Reactive astrocyte biomarkers mirror Alzheimer disease pathology	32
The role of astrocytic α7 nicotinic acetylcholine receptors in Alzheimer disease	31
Prognostic plasma biomarkers for spinal cord injury	31
Origins and immunopathogenesis of autoimmune central nervous system disorders	31
Plasma extracellular vesicle biomarkers for frontotemporal dementia and related disorders	31
Huntington disease-like 2: insight into neurodegeneration from an African disease	31
Inflammasomes in neurological disorders — mechanisms and therapeutic potential	30
The case for low-level BACE1 inhibition for the prevention of Alzheimer disease	29
Facioscapulohumeral muscular dystrophy: the road to targeted therapies	28
Positron emission tomography in multiple sclerosis — straight to the target	27
The Miami Framework for ALS and related neurodegenerative disorders: an integrated view of phenotype and biology	27
Antisense oligonucleotide shows potential in Charcot–Marie–Tooth disease	27
Deep learning distinguishes tauopathies	24
Twin study probes non-heritable immune aspects of multiple sclerosis	24
Neurogenesis altered in multiple neurodegenerative diseases	22
Multiple sclerosis treatment blunts SARS-CoV-2 antibody response	22
High rate of epilepsy in young individuals who died with COVID-19	21
Charting brain development across the human lifespan	21
Genome-wide analysis furthers decoding of Alzheimer disease genetics	20
Serum NfL as an MS biomarker	20
Does antiherpetic antiviral therapy reduce the risk of dementia?	20
The murky waters of sex differences in post-stroke cognitive impairment	19
Aberrant protein networks in Alzheimer disease	19
John Q. Trojanowski	19
ALS pathogenesis linked to actin barrier collapse	19
AI and protein structure and function in neurological disease: relevance to disease management	19
AI aces diagnosis of chronic ataxias	17
Author Correction: The complex aetiology of cerebral palsy	17
Neurological manifestations of rhino-oculo-cerebral mucormycosis in the COVID-19 era	17
BCAS1+ oligodendrocytes aid remyelination in MS	17
Alzheimer disease in African American individuals: increased incidence or not enough data?	16
Pharmacological rehabilitation for stroke	16
Addressing disparities in the global epidemiology of stroke	16
Pathogenetic mechanisms and treatment targets in cerebral malaria	16
Neuroprognostication: a conceptual framework	15
Clocking the age of Parkinson disease onset	14
Molecular biomarkers for vascular cognitive impairment and dementia	14
Addressing racial inequities in neuropsychological assessment requires international prescriptive standards, not demographically adjusted norms	13
Nanoprobe for blood–brain barrier changes	13
Nusinersen treatment response markers	13
Effects of diet on MS onset and course	13
Altered muscle cholesterol transport in ALS	12
Disease-modifying therapies for Parkinson disease: lessons from multiple sclerosis	12
Predictive tools in psychosis: what is ‘good enough’?	12
Mechanistic insights into the interaction between epilepsy and sleep	11
Sex and gender in neurodevelopmental conditions	11
Alzheimer disease seen through the lens of sex and gender	11
Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies	11